Scarica l'app Stockscreener
1.66
1.68%
-0.13
Precedente Chiudi:
$1.79
Aprire:
$1.71
Volume 24 ore:
505
Relative Volume:
0.03
Capitalizzazione di mercato:
$70.31M
Reddito:
$1.88M
Utile/perdita netta:
$-8.48M
Rapporto P/E:
-8.8251
EPS:
-0.1881
Flusso di cassa netto:
$-19.13M
1 W Prestazione:
+0.57%
1M Prestazione:
+2.92%
6M Prestazione:
+15.03%
1 anno Prestazione:
-22.47%
Intervallo 1D:
$1.71
$1.71
Intervallo di 1 settimana:
$1.71
$1.92
Portata 52W:
$1.175
$2.44
Beyondspring Inc Stock (BYSI) Company Profile
Nome
Beyondspring Inc
Settore
Industria
Telefono
646-528-4184
Indirizzo
100 CAMPUS DRIVE, WEST SIDE, 4TH FLOOR, FLORHAM PARK, NY
Compare BYSI vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BYSI
Beyondspring Inc
|
1.71 | 76.89M | 1.88M | -8.48M | -19.13M | -0.1881 |
VRTX
Vertex Pharmaceuticals Inc
|
528.34 | 134.02B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
672.50 | 68.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
925.83 | 58.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.97 | 41.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
191.85 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
Beyondspring Inc Stock (BYSI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-12-02 | Downgrade | BofA Securities | Buy → Underperform |
| 2021-12-02 | Downgrade | Jefferies | Buy → Hold |
| 2021-12-01 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2021-12-01 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2021-09-09 | Iniziato | Robert W. Baird | Outperform |
| 2021-08-04 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2021-04-05 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2021-01-11 | Iniziato | BofA Securities | Buy |
| 2020-12-29 | Iniziato | Evercore ISI | Outperform |
| 2020-02-07 | Iniziato | Jefferies | Buy |
| 2020-01-10 | Iniziato | Nomura | Buy |
| 2019-12-03 | Iniziato | William Blair | Outperform |
| 2019-07-10 | Reiterato | H.C. Wainwright | Buy |
| 2019-04-30 | Downgrade | Maxim Group | Buy → Hold |
| 2018-10-25 | Reiterato | Maxim Group | Buy |
Mostra tutto
Beyondspring Inc Borsa (BYSI) Ultime notizie
Form 4 BeyondSpring Inc For: 6 July By Investing.com - Investing.com Canada
BeyondSpring (BYSI) CEO Qiu Min reports direct holding of 2,498 Ordinary Shares - Stock Titan
BeyondSpring (BYSI) CEO awarded 100,000 stock options at $1.75 strike price - Stock Titan
BeyondSpring (BYSI) CFO Li Na submits initial Form 3 ownership filing - Stock Titan
BeyondSpring Inc. (BYSI) Q1 2026 Earnings: Narrowing Per‑Share Loss Amid Ongoing Pipeline FocusBalance Sheet Strength - dars.gov.et
BeyondSpring (BYSI) finalizes CEO Min Qiu salary, bonus and option grant - Stock Titan
BeyondSpring Inc.(NasdaqCM: BYSI) dropped from Russell 3000E Growth Benchmark - marketscreener.com
BeyondSpring Inc.(NasdaqCM:BYSI) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
BYSI Q1 2026 Earnings: Narrowing Losses Amid Pipeline Progress, Stock Gains 5.6%Pre-Earnings Drift - dars.gov.et
Beyondspring Inc (BYSI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Price to book forward of BeyondSpring, Inc. – NASDAQ:BYSI - TradingView
Price to sales forward of BeyondSpring, Inc. – NASDAQ:BYSI - TradingView
Enterprise value to revenue forward of BeyondSpring, Inc. – NASDAQ:BYSI - TradingView
Beyondspring Inc (BYSI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BeyondSpring Inc. Actuals & Estimates (NASDAQ:BYSI) - TradingView
Beyondspring Inc (BYSI) Valuation: PE, PB & Fair Value Analysis - TradingKey
Beyondspring Inc (BYSI) Institutional Confidence - TradingKey
BeyondSpring Inc. (BYSI) Q1 2026 Earnings: Narrowing Losses Amid Strategic Clinical ProgressAnalyst Drop Coverage - dars.gov.et
Beyondspring Inc (BYSI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Beyondspring Inc (BYSI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Beyondspring Inc (BYSI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Beyondspring Inc (BYSI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Beyondspring Inc (BYSI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
BYSI Q1 2026 Earnings: Net Loss Narrows Amid Ongoing Clinical DevelopmentProfitability Analysis - newsline.com
BYSI Q1 2026 Earnings: Pipeline Progress Amidst Pre-Revenue PhaseNet Profit Margin - newsline.com
BeyondSpring Announces Major Leadership Transition and New CEO - The Globe and Mail
BYSI Q1 2026 Earnings: Loss per Share of $0.05, Stock Declines Amid Quiet QuarterEarnings Miss Streak - newsline.com
BeyondSpring names new CEO as founder transitions to chairman role - StreetInsider
BeyondSpring Elevates Min Qiu to CEO, Names Na Li CFO in Leadership Transition - citybiz
BeyondSpring names new CEO, CFO as founder shifts to chairman role By Investing.com - Investing.com South Africa
BeyondSpring Inc. Announces Appointment of Na Li as Chief Financial Officer, Effective July 1, 2026 - marketscreener.com
BeyondSpring names new CEO, CFO as founder shifts to chairman role - Investing.com Nigeria
BeyondSpring (NASDAQ: BYSI) overhauls leadership to drive DUBLIN-4 lung cancer program - Stock Titan
BeyondSpring Inc. Announces Leadership Transition to Enhance Focus on DUBLIN-4 Program and Plinabulin Development - Quiver Quantitative
BeyondSpring: Lan Huang Remains Chairman >BYSI - Moomoo
BeyondSpring Announces Leadership Transition to Deliver - GlobeNewswire
BeyondSpring (BYSI) Shares Promising Phase 2 Findings for Lung C - GuruFocus
BeyondSpring reports phase 2 lung cancer trial results at ASCO - Investing.com
BeyondSpring reports phase 2 lung cancer trial results at ASCO By Investing.com - Investing.com Canada
Lung cancer trial tests drug trio after immunotherapy, 58% alive at 2 years - Stock Titan
BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026 - GlobeNewswire
BeyondSpring (BYSI) Faces Selling Pressure: Support Levels Tested After 2.33% DeclineSynthetic Short - The Legal Advocate
BYSI Stock Chart | BEYONDSPRING INC (NASDAQ:BYSI) - ChartMill
BYSIBeyondSpring Inc Stock Price and Quote - Finviz
BeyondSpring Q1 2026 Earnings: Narrowed Loss Per Share and Positive Stock MovementEarnings Decline Risk - The Legal Advocate
BeyondSpring (BYSI) Q1 2026 Earnings: Narrowing Loss and No Revenue as Clinical-Stage Biotech Advances PipelineProfit Recovery Report - The Legal Advocate
BYSI Q1 2026 Earnings: Narrow Loss and Modest Stock Gain as Pipeline Progress ContinuesInterim Report - The Legal Advocate
BeyondSpring Q1 2026 Earnings: Narrowing Loss Highlights Pipeline Progress Amid Zero RevenueTrending Buy Opportunities - Newser
BeyondSpring Inc. to Present Study 303 on Plinabulin Combination Therapy for NSCLC at ASCO 2026 - Quiver Quantitative
Phase 2 plinabulin combo in resistant NSCLC to appear at 2026 ASCO - Stock Titan
BYSI BeyondSpring beats Q4 EPS estimates by 11 but shares drop 25 on zero revenueValue Pick - Newser
Beyondspring Inc Azioni (BYSI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Beyondspring Inc Azioni (BYSI) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Decheng Capital China Life Sci | 10% Owner |
Oct 17 '25 |
Sale |
1.76 |
45,513 |
80,103 |
1,518,893 |
| Decheng Capital China Life Sci | 10% Owner |
Oct 13 '25 |
Sale |
1.70 |
107,361 |
182,514 |
1,696,659 |
| Decheng Capital China Life Sci | 10% Owner |
Oct 14 '25 |
Sale |
1.65 |
28,495 |
47,017 |
1,668,164 |
| Decheng Capital China Life Sci | 10% Owner |
Oct 15 '25 |
Sale |
1.65 |
17,960 |
29,634 |
1,650,204 |
| Decheng Capital China Life Sci | 10% Owner |
Oct 08 '25 |
Sale |
1.77 |
7,507 |
13,287 |
1,810,389 |
| Decheng Capital China Life Sci | 10% Owner |
Oct 09 '25 |
Sale |
1.81 |
3,979 |
7,202 |
1,806,410 |
| Decheng Capital China Life Sci | 10% Owner |
Oct 10 '25 |
Sale |
1.77 |
2,390 |
4,230 |
1,804,020 |
| Decheng Capital China Life Sci | 10% Owner |
Oct 06 '25 |
Sale |
1.78 |
17,500 |
31,150 |
1,819,996 |
| Decheng Capital China Life Sci | 10% Owner |
Oct 07 '25 |
Sale |
1.79 |
2,100 |
3,759 |
1,817,896 |
| Decheng Capital China Life Sci | 10% Owner |
Oct 03 '25 |
Sale |
1.76 |
600 |
1,056 |
1,837,496 |
1.61%
3.59%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):